Sun Pharmaceutical Industries posts consolidated Q2 FY26 PAT higher at Rs. 3,137.09 Cr
Sun Pharmaceutical Industries has reported total income of Rs. 14,948.23 crore during the period ended September 30, 2025
Sun Pharmaceutical Industries has reported total income of Rs. 14,948.23 crore during the period ended September 30, 2025
A bio-analytical Remote Regulatory Assessment was also conducted from October 30 to November 7, 2025, and concluded with no observations
Olaparib is indicated for the treatment of certain types of ovarian, breast, pancreatic, and prostate cancers
Sumatriptan injection is indicated in adults for the acute treatment of migraine
The approved ANDA is therapeutically equivalent to the reference listed drug (RLD), Sprycel Tablets
Sales from Novo’s GLP-1 portfolio—including Wegovy for obesity and Ozempic for type 2 diabetes reached $5.6 billion
Comirnaty, Pfizer’s COVID-19 prevention vaccine, reported global sales of $1.15 billion
The device delivers clear, high-quality images to support accurate diagnoses across a broad range of patient groups
Adjusted EBITDA increased by 12.3 per cent to $531 million, up from $516 million in the same period last year
Subscribe To Our Newsletter & Stay Updated